Compare ACNB & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACNB | DRUG |
|---|---|---|
| Founded | 1857 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 659.3M | 778.4M |
| IPO Year | 1994 | 2020 |
| Metric | ACNB | DRUG |
|---|---|---|
| Price | $63.36 | $80.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $58.00 | ★ $129.25 |
| AVG Volume (30 Days) | 63.8K | ★ 206.5K |
| Earning Date | 04-23-2026 | 05-15-2026 |
| Dividend Yield | ★ 3.00% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.81 | N/A |
| Revenue | ★ $191,821,000.00 | N/A |
| Revenue This Year | $13.18 | N/A |
| Revenue Next Year | $1.91 | N/A |
| P/E Ratio | $22.91 | ★ N/A |
| Revenue Growth | ★ 45.10 | N/A |
| 52 Week Low | $42.60 | $38.00 |
| 52 Week High | $65.94 | $123.75 |
| Indicator | ACNB | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 56.47 | 62.13 |
| Support Level | $48.10 | $79.55 |
| Resistance Level | $65.94 | $84.29 |
| Average True Range (ATR) | 1.50 | 3.71 |
| MACD | -0.11 | 0.73 |
| Stochastic Oscillator | 57.17 | 86.23 |
ACNB Corp is the financial holding company. Through its wholly-owned subsidiaries, it provides a full range of retail and commercial financial services in Pennsylvania and Maryland through its network of community banking offices. It also provides property, casualty, health, life and disability insurance serving personal and commercial clients through offices in Westminster, Maryland, and Gettysburg, Pennsylvania and is licensed to do business. The corporation has two reporting segments; the Banking segment which generates the majority of the revenue from banking and wealth management services, including trust and retail brokerage; and ACNB Insurance Services segment which offers a broad range of property and casualty, life and health insurance to both commercial and individual clients.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.